Skip to main content

Healthy Volunteer

224
Pipeline Programs
30
Companies
50
Clinical Trials
17 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
222
1
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3870%
Monoclonal Antibody
1120%
RNA Therapeutic
36%
Bispecific Antibody
24%
+ 289 programs with unclassified modality

Competitive Landscape

88 companies ranked by most advanced pipeline stage

Biocorp
19 programs
18
1
CarotenoidsPhase 41 trial
Acyclovir 800 mg TabletPhase 11 trial
Alfuzosin Hydrochloride 10 mg Prolonged-release TabletsPhase 11 trial
Amlodipine/ValsartanPhase 1Small Molecule1 trial
Apixaban 5MGPhase 11 trial
+14 more programs
Active Trials
NCT06228430Unknown40Est. Feb 2024
NCT06228339Unknown44Est. Mar 2024
NCT06193044Unknown48Est. Jul 2024
+13 more trials
Human BioSciences
1
Walking on a TreadmillPhase 1/21 trial
Information absentN/A1 trial
Active Trials
NCT00669188Completed326Est. Jul 2020
NCT01888939Completed89Est. Jan 2018
Genentech
78 programs
62
BasmisanilPhase 11 trial
CMSPhase 11 trial
CarbamazepinePhase 11 trial
FluvoxaminePhase 11 trial
GDC-0973Phase 11 trial
+73 more programs
Active Trials
NCT01926873Completed240Est. Jul 2014
NCT03959332Completed32Est. Jul 2019
NCT00520273Completed100,000Est. Oct 2007
+75 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
19 programs
19
ABBV-101Phase 11 trial
ABBV-1042Phase 1
ABBV-1088Phase 11 trial
ABBV-1354Phase 11 trial
ABBV-382Phase 11 trial
+14 more programs
Active Trials
NCT06887010Completed17Est. Sep 2025
NCT06579300Terminated72Est. Sep 2025
NCT07219017Completed8Est. Dec 2025
+13 more trials
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
19 programs
19
AZD1236Phase 11 trial
AZD1722Phase 11 trial
AZD2423Phase 11 trial
AZD6280Phase 11 trial
AZD6280Phase 11 trial
+14 more programs
Active Trials
NCT00767052Completed48Est. Dec 2008
NCT02176252Completed83Est. Dec 2013
NCT00970775Completed32Est. Dec 2009
+16 more trials
Pfizer
PfizerNEW YORK, NY
11 programs
11
AG-013736Phase 11 trial
ErtugliflozinPhase 1Small Molecule
Lersivirine Immediate-ReleasePhase 1
PF 06835919Phase 11 trial
PF-02341066Phase 11 trial
+6 more programs
Active Trials
NCT01020136Completed42Est. Feb 2010
NCT03916406Completed10Est. Jun 2019
NCT01082380Completed6Est. Apr 2010
+6 more trials
Shionogi
9 programs
8
DarunavirPhase 1Small Molecule
GSK1349572Phase 1
GSK1349572Phase 1
GSK1349572 and MaaloxAdvanced Maximum StrengthPhase 1
Radio-labelled S-770108Phase 11 trial
+4 more programs
Active Trials
NCT04631354Completed12Est. Dec 2020
NCT04147715Completed98Est. Sep 2020
NCT03897413Completed15Est. Dec 2009
ViiV Healthcare
8 programs
8
DarunavirPhase 1Small Molecule
GSK1349572Phase 1
GSK1349572Phase 1
GSK1349572 and MaaloxAdvanced Maximum StrengthPhase 1
Lersivirine Immediate-ReleasePhase 1
+3 more programs
Allergy Therapeutics
3
AMA1-C1/Alhydrogel + CpG 7909Phase 11 trial
Ad4-Env145NFLPhase 11 trial
Ad4-H5-VtnPhase 11 trial
Collection of Data and Samples From Healthy Donors for Use in Translational ResearchN/A1 trial
FlucelvaxPHASE_21 trial
Active Trials
NCT00090662Recruiting150
NCT04025580Completed98Est. Jan 2023
NCT00340574Completed0Est. Jul 2008
+2 more trials
Supernus Pharmaceuticals
5
SAGE-718Phase 11 trial
SAGE-718Phase 11 trial
SAGE-718Phase 11 trial
SAGE-904Phase 11 trial
SPN-817, Treatment BPhase 11 trial
Active Trials
NCT03844906Completed40Est. Apr 2019
NCT03770780Completed19Est. Mar 2019
NCT03771586Completed22Est. Jan 2019
+2 more trials
Tanabe Pharma America
4
MT-7117Phase 11 trial
MT-8554 Low dosePhase 11 trial
[14C] MT-7117Phase 11 trial
[14C] MT-8554Phase 11 trial
Active Trials
NCT03688022Completed50Est. Dec 2018
NCT03471130Completed48Est. Oct 2018
NCT03503266Completed6Est. May 2018
+1 more trials
Immunome
4 programs
4
varegacestatPhase 1Small Molecule1 trial
varegacestatPhase 1Small Molecule1 trial
varegacestatPhase 1Small Molecule1 trial
varegacestatPhase 1Small Molecule1 trial
Active Trials
NCT06677996Completed22Est. May 2025
NCT06845852Completed6Est. Mar 2025
NCT06855264Completed32Est. May 2025
+1 more trials
Quotient Therapeutics
3
ANG-3777Phase 11 trial
AQX-1125 Oral TabletPhase 11 trial
Capivasertib film-coated tablet, 200 mgPhase 1
Active Trials
NCT04898907Unknown48Est. Sep 2021
NCT03185195Completed9Est. Jan 2017
Astellas
AstellasChina - Shenyang
3 programs
3
ASP1941Phase 12 trials
YM150Phase 11 trial
YM150Phase 11 trial
Active Trials
NCT01316107Completed122Est. Oct 2012
NCT01121198Completed84Est. Jul 2007
NCT01125670Completed24Est. Apr 2010
+1 more trials
Biocon
3 programs
3
Biocon Insulin NPhase 11 trial
Biocon Insulin RPhase 11 trial
Humulin ®70/30Phase 11 trial
Active Trials
NCT04022304Completed90Est. Dec 2019
NCT04022317Completed42Est. Sep 2019
NCT04022291Completed78Est. Jan 2020
Hanmi Pharmaceutical
3
HIP1601 40mgPhase 11 trial
HIP1802Phase 11 trial
HIP2105Phase 11 trial
Active Trials
NCT04204629Completed25Est. Feb 2020
NCT04324905Completed49Est. Oct 2020
NCT04975711Completed48Est. Nov 2021
Prevail Therapeutics
3
LY110140Phase 1
LY2495655Phase 1
LY3009104Phase 1
Agios Pharmaceuticals
2
AG-348Phase 11 trial
AG-348Phase 11 trial
Active Trials
NCT02108106Completed48Est. Aug 2014
NCT02149966Completed48Est. Nov 2014
Disc Medicine
2 programs
2
DISC-0974Phase 11 trial
DISC-3405Phase 11 trial
Active Trials
NCT04999527Completed42Est. Jun 2022
NCT06050915Completed64Est. Jul 2024
Meiji Seika Pharma
2
DMB-3111Phase 11 trial
DMB-3113Phase 11 trial
Active Trials
NCT02100917Completed70Est. Dec 2014
NCT02927353Completed180Est. Jan 2017
MSD
2 programs
2
ErtugliflozinPhase 1Small Molecule1 trial
RaltegravirPhase 1Small Molecule1 trial
Active Trials
NCT01018823Completed40Est. Mar 2010
NCT01325051Completed15Est. Nov 2011
Sharp Therapeutics
2
ErtugliflozinPhase 1Small Molecule
RaltegravirPhase 1Small Molecule
BioTherapeutics Inc
2
IRL201104Phase 1
IRL201104Phase 1
Belite Bio
2 programs
2
LBS-008Phase 11 trial
TinlarebantPhase 11 trial
Active Trials
NCT03735810Completed71Est. Sep 2019
NCT05667688Completed15Est. Jan 2023
Advenchen Laboratories
1
AL3818 CapsulePhase 11 trial
Active Trials
NCT07438886Not Yet Recruiting16Est. Mar 2027
Emergent BioSolutions
1
Ad4-mgagPhase 11 trial
Active Trials
NCT02771730Terminated20Est. Feb 2017
Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY1101042Phase 11 trial
Active Trials
NCT03252002Completed96Est. Jul 2019
Aligos Therapeutics
1
CarbamazepinePhase 11 trial
Active Trials
NCT06672900Active Not Recruiting24Est. Jul 2025
InventisBio
1 program
1
D-2570Phase 11 trial
Active Trials
NCT07270783Recruiting36Est. Jun 2026
Dren Bio
1 program
1
DR-01Phase 1

+58 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
BiocorpCarotenoids
Nurix TherapeuticsNX-5948
RegeneronREGN7508
AstellasASP1941
Biomea FusionIcovamenib
Biomea FusionIcovamenib
RegeneronREGN7508
TakedaTAK-951
Allergy TherapeuticsFlucelvax
Bristol Myers SquibbCC-90001
Bristol Myers SquibbCC-220
Bristol Myers SquibbCC-90001
Bristol Myers SquibbCC-220
Bristol Myers SquibbCC-220
Nurix TherapeuticsNX-5948

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,589 patients across 50 trials

CaroRite™ for Skin Health and Signs of Ageing

Start: Jul 2025Est. completion: Dec 202580 patients
Phase 4Completed

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

Start: Jun 2026Est. completion: Jun 2032620 patients
Phase 3Not Yet Recruiting

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Start: Apr 2026Est. completion: Jul 20311,600 patients
Phase 3Not Yet Recruiting

A Study to Assess Safety and Efficacy of ASP1941 in Combination With Nateglinide in Type 2 Diabetic Patients

Start: Jan 2011Est. completion: Oct 2012122 patients
Phase 3Completed

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Start: Apr 2026Est. completion: Jul 202760 patients
Phase 2Recruiting

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets

Start: Mar 2026Est. completion: Jul 202760 patients
Phase 2Recruiting

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Start: Oct 2025Est. completion: Apr 20271,200 patients
Phase 2Recruiting

A Study of TAK-951 to Stop Adults Getting Nausea and Vomiting After Planned Surgery

Start: Oct 2020Est. completion: Mar 202289 patients
Phase 2Completed

Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Start: Oct 2019Est. completion: Jan 202398 patients
Phase 2Completed

Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Start: Aug 2019Est. completion: Sep 202156 patients
Phase 2Terminated

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Start: Aug 2017Est. completion: Aug 2021289 patients
Phase 2Completed

A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis

Start: Jul 2017Est. completion: Dec 2021138 patients
Phase 2Terminated

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Start: Nov 2014Est. completion: Jun 20170
Phase 2Withdrawn

A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.

Start: Sep 2014Est. completion: Sep 201842 patients
Phase 2Completed

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Start: May 2026Est. completion: May 2033150 patients
Phase 1/2Not Yet Recruiting

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Start: Feb 2021Est. completion: Sep 202127 patients
Phase 1/2Completed

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

Start: Dec 2017Est. completion: Feb 202362 patients
Phase 1/2Completed
NCT01888939Human BioSciencesWalking on a Treadmill

Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children

Start: Jun 2013Est. completion: Jan 201889 patients
Phase 1/2Completed
NCT07357909NobleHydrogen-Oxygen Ultrafine Bubbles

Safety Study of Intravenous Hydrogen-Oxygen Ultrafine Bubbles in Adults

Start: May 2026Est. completion: Dec 202650 patients
Phase 1Not Yet Recruiting

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Start: Mar 2026Est. completion: Jul 202616 patients
Phase 1Recruiting
NCT07439263Hinge BioHB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody with Dual Fc Domains

Single Ascending Dose Study of HB2198 in Healthy Participants

Start: Mar 2026Est. completion: Aug 202632 patients
Phase 1Recruiting

Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers

Start: Mar 2026Est. completion: Mar 202716 patients
Phase 1Not Yet Recruiting

A Study to Assess How the Body Absorbs ABBV-8736 Subcutaneous Injections Relative to Intravenous Injections in Adult Healthy Volunteers

Start: Feb 2026Est. completion: Jun 202640 patients
Phase 1Active Not Recruiting

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

Start: Jan 2026Est. completion: Mar 202611 patients
Phase 1Completed

A Study to Learn More About the Safety of BIIB145 and How it is Processed in the Body of Healthy Adult Participants

Start: Dec 2025Est. completion: Feb 2027104 patients
Phase 1Recruiting
NCT07297199BiogenOmaveloxolone

A Study to Learn How the Body Processes BIIB141 (Omaveloxolone) When Taken as a Capsule or as a Tablet Dissolved in Liquid, and to Learn About Its Safety in Healthy Adults Ages 18 to 55

Start: Dec 2025Est. completion: May 202670 patients
Phase 1Recruiting

Healthy Volunteer Study

Start: Dec 2025Est. completion: Jun 202636 patients
Phase 1Recruiting

A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 Diabetes

Start: Nov 2025Est. completion: Nov 202772 patients
Phase 1Recruiting
NCT07261371PfizerTest formulation

A Study to Compare Blood Levels of Different Dosage Formulations of the Study Medicine That Is a CGRP Receptor Antagonist in Healthy Adults

Start: Nov 2025Est. completion: May 202664 patients
Phase 1Recruiting

A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants

Start: Oct 2025Est. completion: Dec 20258 patients
Phase 1Completed
NCT07215078Pfizeratirmociclib

Study About Whether Atirmociclib/PF-07220060 Proportionally Increases Exposure as Dose Increases in Healthy Participants

Start: Oct 2025Est. completion: Jun 202672 patients
Phase 1Recruiting

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

Start: Oct 2025Est. completion: Jun 2026142 patients
Phase 1Recruiting

Comparison of DW-1021 and Separate Doses of Pelubi CR and Zytram CR Under Fasting Conditions

Start: Sep 2025Est. completion: Oct 202514 patients
Phase 1Recruiting

Food Effect Study in Healthy Volunteers

Start: Sep 2025Est. completion: Jan 202660 patients
Phase 1Completed
NCT07149415BiogenOmaveloxolone

A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55

Start: Sep 2025Est. completion: Oct 202522 patients
Phase 1Completed

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

Start: Aug 2025Est. completion: Aug 202678 patients
Phase 1Recruiting

A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants

Start: May 2025Est. completion: Sep 202546 patients
Phase 1Completed

First-In-Human Study to Evaluate Single and Multiple Ascending Doses of JUV-161 in Healthy Adult Volunteers

Start: Apr 2025Est. completion: Jun 202672 patients
Phase 1Active Not Recruiting
NCT07416955Kashiv BioSciencesTPI-120 Pre-Filled Syringe 6 mg/0.6 mL

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

Start: Apr 2025Est. completion: Oct 2025180 patients
Phase 1Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Subcutaneous or Intravenous Doses of ABBV-701 in Healthy Adult Western and Asian Participants

Start: Apr 2025Est. completion: Nov 2026100 patients
Phase 1Active Not Recruiting

A Phase 1 Study of S-4321

Start: Apr 2025Est. completion: Apr 202696 patients
Phase 1Recruiting

A Study to Assess How Food Affects the Movement of Oral ABBV-101 Through the Body of Healthy Adult Participants

Start: Mar 2025Est. completion: Sep 202517 patients
Phase 1Completed

ENX-205 SAD/PET Study in Healthy Adults

Start: Mar 2025Est. completion: Apr 202660 patients
Phase 1Recruiting

A Varegacestat Hepatic Impairment Study

Start: Mar 2025Est. completion: Mar 202635 patients
Phase 1Completed

Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults

Start: Mar 2025Est. completion: Jul 202656 patients
Phase 1Active Not Recruiting

Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults

Start: Mar 2025Est. completion: Jan 202672 patients
Phase 1Completed

A Study of Subcutaneous DR-01 in Healthy Volunteers

Start: Mar 2025Est. completion: Aug 202532 patients
Phase 1Completed

A Phase 1 Study of S-1117

Start: Mar 2025Est. completion: Mar 202696 patients
Phase 1Recruiting

A Phase 1 Mass Balance Study of Varegacestat

Start: Feb 2025Est. completion: Mar 20256 patients
Phase 1Completed

A Cardiac Liability Study of Varegacestat in Healthy Participants

Start: Feb 2025Est. completion: May 202532 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

17 actively recruiting trials targeting 6,589 patients
30 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.